Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke MultiStem® stem cell technology receives Positive Opinion from European Medicines Agency   Adds to Special Protocol Assessment and Fast Track designation in U.S., and Priority Review under Sakigake...

Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem® CLEVELAND, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the...